Multiple Myeloma Coverage from Every Angle


Predictive Model in Multiple Myeloma: Focus on Pyroptosis-Related Genes
KarMMa-3 Trial Update: Use of Idecabtagene Vicleucel in Resistant Multiple Myeloma
Extended Genetic Profiling May Improve Risk Prediction in Transplant-Eligible Patients With Myeloma
Does the Addition of Upfront Autologous HSCT Improve Outcomes in Patients With Multiple Myeloma?
Novel SK2 Inhibitor Under Study in Resistant Multiple Myeloma
18-Month Follow-up on Ciltacabtagene Autoleucel in Patients With Multiple Myeloma
Comparison of Standard Therapies for Transplantation-Ineligible Patients With Myeloma
Potential Genomic Mechanisms of Resistance to Targeted Immunotherapy for Myeloma
Salvage Therapies After Myeloma Progression on CAR T-Cell Therapy
CAR T-Cell Therapy After BCMA-Targeted Therapy for Resistant Multiple Myeloma
Immunologic Profile of Patients With High-Risk Smoldering Myeloma
Extended Consolidation Therapy After ASCT for Ultra–High-Risk Multiple Myeloma
Large Single-Cell RNA-Sequencing Cohort Sheds Light on Precursor Conditions to Multiple Myeloma
Updated Results From Cohort C of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Multiple Myeloma
Subcutaneous, On-Body Delivery of Isatuximab-irfc for Resistant Multiple Myeloma
Dose-Expansion Results of Mezigdomide-Based Therapy for Advanced Multiple Myeloma
Cohort 2C of KarMMa-2: Idecabtagene Vicleucel for High-Risk Multiple Myeloma
What Is the Optimal Duration of Lenalidomide Maintenance Therapy After ASCT?
BCMA/CD19 Dual-Targeting CAR T-Cell Therapy for Multiple Myeloma
Use of Bortezomib and Lenalidomide in Conjunction With ASCT in Myeloma
Tocilizumab Pretreatment Followed by Cevostamab for Resistant Myeloma
ASH 2022: Quadruplet Regimen Under Study in High-Risk Smoldering Multiple Myeloma
ASH 2022: Dose-Escalation Study Evaluates T-Cell–Engaging Bispecific Antibody in Resistant Myeloma
ASH 2022: Influence of Microenvironment Changes on Achieving Sustained Remission in Myeloma
ASH 2022: Does KDM6A Expression Modulate the Efficacy of Daratumumab in Myeloma?
ASH 2022: Dexamethasone-Sparing Regimen for Elderly Patients With Multiple Myeloma
ASH 2022: Bispecific Antibody Elranatamab in Patients Under Study in Aggressive Multiple Myeloma
ASH 2022: Can Intensive Treatment Regimen Reduce the Risk of Disease Progression in Smoldering Myeloma?
ASH 2022: First-in-Human Study of Modakafusp Alfa in Resistant Multiple Myeloma
ASH 2022: Phase I/II Results of CD3 Bispecific Antibody in Resistant Multiple Myeloma
ASH 2022: Early-Phase Trial Evaluates Elranatamab in Resistant Multiple Myeloma
Photon-Counting Detector CT May Improve the Visibility of Multiple Myeloma Lesions
Exploring the Use of Translationally Controlled Proteins in the Treatment of Multiple Myeloma
Sequential Combinations of Different T-Cell Redirection Therapies in Resistant Myeloma
SITC 2022: Cellular Research May Lead to the Next Generation of Therapies for Myeloma
Should Routine Stem Cell Transplantation Be Discontinued in Newly Diagnosed Patients With Myeloma?
SITC 2022: Antigen-Specific Memory CD8-Positive T Cells Target BCMA to Treat Multiple Myeloma
ASTRO 2022: CNS-Directed Radiotherapy for Patients With Extramedullary Multiple Myeloma
ASTRO 2022: Can Radiotherapy Prevent Progression to Myeloma in Patients With Plasmacytomas?
FDA Brief: Bispecific Antibody Receives Breakthrough Therapy Designation in Resistant Myeloma
SLAMF7 Antigen and Myeloma: Therapeutic Target for Antibody-Based and Cellular Immunotherapy?
Daratumumab-Based Chemoimmunotherapy for Multiple Myeloma: Focus on Advanced Renal Failure
ASTRO 2022: Community-Based Registry Offers Glimpse at Use of Radiotherapy for Myeloma
FDA Brief: Teclistamab-cqyv Granted Accelerated Approval in Resistant Myeloma
CD38-CAR Natural Killer Cells: Potential Immunotherapy Target in Multiple Myeloma?
SOHO 2022: Exploring the Role of Salvage Autologous HCT in Myeloma
Gut Microbiota and Gastrointestinal Toxicity From Proteasome Inhibitors in Myeloma
Early-Phase Research on Sotatercept in Combination Therapy for Resistant Multiple Myeloma
SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma
Can a Mutational Signature Predict Outcomes With Carfilzomib-Based Therapy for Myeloma?
ASCO Quality 2022: Underrepresentation of Black Patients in Multiple Myeloma Clinical Trials
BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma
Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?
Red Cell Distribution Width: A Prognostic Indicator in Newly Diagnosed Multiple Myeloma?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.